PF-Atlas › Clinical Trials › FASUDIL-IPF

Inhaled Fasudil ROCK Inhibitor in IPF — Japan

Fasudil · ROCK Inhibition · Phase 2

Registry ID
FASUDIL-IPF
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Fasudil
Mechanism
ROCK Inhibition
Sponsor
Japan Multi-center
Start
2022-03

About this trial

Fasudil is evaluated in FASUDIL-IPF, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Japan Multi-center, targeting rock inhibition. Current status: Active, not recruiting.

View FASUDIL-IPF on ClinicalTrials.gov →

Explore related

ROCK Inhibitor — Inhaled Fasudil — Treatment profileAll Fasudil trialsROCK Inhibition mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for FASUDIL-IPF for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.